Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.

Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study.

COVID-19 has been linked to cases of new-onset diabetes, diabetes-related emergencies and a higher death rate among diabetes patients.

Vanderbilt University Medical Center researchers have discovered individuals with type 1 and type 2 diabetes infected with COVID-19 are three times more likely to have a severe illness or require hospitalization compared with people without diabetes.

A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.